Success Metrics

Clinical Success Rate
57.1%

Based on 4 completed trials

Completion Rate
57%(4/7)
Active Trials
2(20%)
Results Posted
100%(4 trials)
Terminated
3(30%)

Phase Distribution

Ph phase_3
2
20%
Ph phase_2
3
30%
Ph phase_1
5
50%

Phase Distribution

5

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
5(50.0%)
Phase 2Efficacy & side effects
3(30.0%)
Phase 3Large-scale testing
2(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

4 of 8 finished

Non-Completion Rate

50.0%

4 ended early

Currently Active

2

trials recruiting

Total Trials

10

all time

Status Distribution
Active(2)
Completed(4)
Terminated(4)

Detailed Status

Completed4
Terminated3
Recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
2
Success Rate
57.1%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (50.0%)
Phase 23 (30.0%)
Phase 32 (20.0%)

Trials by Status

withdrawn110%
terminated330%
recruiting220%
completed440%

Recent Activity

2 active trials
Showing 5 of 10
recruitingphase_1

Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

NCT06327100
terminatedphase_1

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

NCT04405167
recruitingphase_1

Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition

NCT06605586
completedphase_2

Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT02159950
terminatedphase_3

Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer

NCT02057666
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT06327100Phase 1

Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Recruiting
NCT04405167Phase 1

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

Terminated
NCT06605586Phase 1

Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition

Recruiting
NCT02159950Phase 2

Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Completed
NCT02057666Phase 3

Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer

Terminated
NCT01732549Phase 2

A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy

Terminated
NCT01743469Phase 2

A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers

Completed
NCT01513733Phase 1

The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer

Completed
NCT02396368Phase 1

A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer

Withdrawn
NCT01234311Phase 3

A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10